Floatz logo

Teriflunomide

Progressive Relapsing Multiple Sclerosis

SanofiSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Progressive Relapsing Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Tolebrutinib
Sanofi
Phase 3B
Corticotropin
University of Minnesota
Phase 2CCC

Same molecule, other indications

Teriflunomide is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
74 / 100
View asset →
multiple sclerosisActive
BBB
Indicative · Phase 4
72 / 100
View asset →
secondary progressive multiple sclerosisActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →